30 related articles for article (PubMed ID: 3276399)
1. Deoxyguanosine-resistant leukemia L1210 cells. Loss of specific deoxyribonucleoside kinase activity.
Cory AH; Shibley IA; Chalovich JM; Cory JG
J Biol Chem; 1993 Jan; 268(1):405-9. PubMed ID: 8380161
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Szekeres T; Gharehbaghi K; Fritzer M; Woody M; Srivastava A; van't Riet B; Jayaram HN; Elford HL
Cancer Chemother Pharmacol; 1994; 34(1):63-6. PubMed ID: 8174204
[TBL] [Abstract][Full Text] [Related]
3. Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
Matsumoto M; Tihan T; Cory JG
Cancer Chemother Pharmacol; 1990; 26(5):323-9. PubMed ID: 2208572
[TBL] [Abstract][Full Text] [Related]
4. Growth, ribonucleotide reductase and metals in murine leukemic lymphocytes.
Oblender M; Carpentieri U
J Cancer Res Clin Oncol; 1991; 117(5):444-8. PubMed ID: 1890140
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.
Kwon NS; Stuehr DJ; Nathan CF
J Exp Med; 1991 Oct; 174(4):761-7. PubMed ID: 1717630
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase as a chemotherapeutic target.
Cory JG
Adv Enzyme Regul; 1988; 27():437-55. PubMed ID: 3074632
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
8. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
9. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Sato A; Montgomery JA; Cory JG
Cancer Res; 1984 Aug; 44(8):3286-90. PubMed ID: 6611198
[TBL] [Abstract][Full Text] [Related]
11. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
12. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
13. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.
Finch RA; Liu MC; Cory AH; Cory JG; Sartorelli AC
Adv Enzyme Regul; 1999; 39():3-12. PubMed ID: 10470363
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
